1.0000
0.0000
(0.00%)
At close: April 10 at 4:00:00 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-470,222
-629,296
-859,108
-589,895
-364,667
Investing Cash Flow
358,042
632,614
743,901
-53,257
-607,131
Financing Cash Flow
-80
-197
162,310
604,146
850,076
End Cash Position
93,019
145,052
145,998
101,352
140,810
Capital Expenditure
-18,160
-9,398
-27,058
-30,931
-9,286
Issuance of Capital Stock
--
--
360
10,000
850,077
Issuance of Debt
--
60,000
161,950
594,564
--
Repayment of Debt
--
-60,000
--
--
--
Repurchase of Capital Stock
-80
-197
--
-418
--
Free Cash Flow
-488,382
-638,694
-886,166
-620,826
-373,953
12/31/2020 - 7/17/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
2GH.BE Merus NV
36.80
+6.36%
RPD.MU Royalty Pharma plc
28.20
-3.09%
ARDX.MX Ardelyx, Inc.
105.50
0.00%
2HA.F Spero Therapeutics, Inc.
0.4965
-7.20%
7PO.F Poxel S.A.
0.5300
0.00%
BT3.BE Lineage Cell Therapeutics Inc
0.3580
-2.72%
B9A.F BioArctic AB (publ)
14.71
-0.94%
HQ1.MU Oruka Therapeutics Inc. R
6.40
0.00%
P0F.F Egetis Therapeutics AB (publ)
0.3270
+2.35%
DBV.F DBV Technologies S.A.
1.1700
+4.09%